Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database.
作者:
主题词
老年人(Aged);心血管疾病(Cardiovascular Diseases);队列研究(Cohort Studies);数据库, 事实型(Databases, Factual);红细胞生成(Erythropoiesis);红细胞生成素(Erythropoietin);女(雌)性(Female);营利性保险计划(For-Profit Insurance Plans);人类(Humans);男(雄)性(Male);Medicare(Medicare);中年人(Middle Aged);肾透析(Renal Dialysis);肾功能不全, 慢性(Renal Insufficiency, Chronic);回顾性研究(Retrospective Studies);治疗结果(Treatment Outcome);美国(United States)
DOI
10.1053/j.ajkd.2014.05.013
PMID
25011692
发布时间
2021-10-21
- 浏览53
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文